[go: up one dir, main page]

MA34723B1 - Compositions et méthodes de traitement de la myélofibrose - Google Patents

Compositions et méthodes de traitement de la myélofibrose

Info

Publication number
MA34723B1
MA34723B1 MA35978A MA35978A MA34723B1 MA 34723 B1 MA34723 B1 MA 34723B1 MA 35978 A MA35978 A MA 35978A MA 35978 A MA35978 A MA 35978A MA 34723 B1 MA34723 B1 MA 34723B1
Authority
MA
Morocco
Prior art keywords
methods
myelfibrosis
treating
compositions
amino
Prior art date
Application number
MA35978A
Other languages
English (en)
Inventor
Janice Cacace
Ayalew Tefferi
Arvind Jayan
Original Assignee
Targegen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34723(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targegen Inc filed Critical Targegen Inc
Publication of MA34723B1 publication Critical patent/MA34723B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSITIONS ET DES MÉTHODES DE TRAITEMENT DE LA MYÉLOFIBROSE CHEZ UN SUJET. LESDITES MÉTHODES COMPRENNENT L'ADMINISTRATION, AUDIT SUJET, D'UNE QUANTITÉ EFFICACE DE COMPOSÉ QUI EST DU N-TERT-BUTYLE-3-[(5-MÉTHYLE-2-{[4-(2-PYRROLIDIN-1-YLÉTHOXY)PHÉNYL]AMINO} PYRIMIDIN-4-YL)AMINO]BENZÈNESULFONAMIDE OU SON SEL PHARMACEUTIQUE OU SON HYDRATE
MA35978A 2010-11-07 2013-06-05 Compositions et méthodes de traitement de la myélofibrose MA34723B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41092410P 2010-11-07 2010-11-07
PCT/US2011/059643 WO2012061833A1 (fr) 2010-11-07 2011-11-07 Compositions et méthodes de traitement de la myélofibrose

Publications (1)

Publication Number Publication Date
MA34723B1 true MA34723B1 (fr) 2013-12-03

Family

ID=46024747

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35978A MA34723B1 (fr) 2010-11-07 2013-06-05 Compositions et méthodes de traitement de la myélofibrose

Country Status (36)

Country Link
US (5) US10391094B2 (fr)
EP (2) EP4159216A1 (fr)
JP (1) JP6133211B2 (fr)
KR (4) KR20240029118A (fr)
CN (2) CN108125923A (fr)
AU (2) AU2010363329A1 (fr)
BR (1) BR112013011184A2 (fr)
CA (2) CA2816957A1 (fr)
CL (1) CL2013001252A1 (fr)
CO (1) CO6801724A2 (fr)
DK (1) DK2635282T3 (fr)
DO (1) DOP2013000097A (fr)
EC (1) ECSP13012658A (fr)
ES (1) ES2930650T3 (fr)
HR (1) HRP20221269T1 (fr)
HU (1) HUE060254T2 (fr)
IL (1) IL226101A (fr)
LT (1) LT2635282T (fr)
MA (1) MA34723B1 (fr)
MX (2) MX381913B (fr)
MY (1) MY161164A (fr)
NI (1) NI201300038A (fr)
NZ (1) NZ611363A (fr)
PE (1) PE20140389A1 (fr)
PH (1) PH12013500924A1 (fr)
PL (1) PL2635282T3 (fr)
PT (1) PT2635282T (fr)
RS (1) RS63996B1 (fr)
RU (1) RU2616262C2 (fr)
SG (1) SG190134A1 (fr)
SI (1) SI2635282T1 (fr)
SM (1) SMT202200453T1 (fr)
TW (1) TWI531389B (fr)
UA (1) UA114076C2 (fr)
WO (2) WO2012060847A1 (fr)
ZA (1) ZA201303423B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CA2816957A1 (fr) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procedes de traitement de la myelofibrose
WO2013059548A1 (fr) * 2011-10-19 2013-04-25 Sanofi Compositions et méthodes de traitement du cancer à l'aide d'un inhibiteur de jak2
ES2634020T3 (es) * 2013-03-06 2017-09-26 Novartis Ag Formulaciones de compuestos orgánicos
CN104771761A (zh) * 2015-03-19 2015-07-15 深圳国源国药有限公司 一种创新药用辅料硅化微晶纤维素及其制备方法
EP3327441B1 (fr) * 2015-07-24 2021-02-17 Public University Corporation Nagoya City University Méthode d'aide au diagnostic d'affections de type myélofibrose, méthode de surveillance d'un effet thérapeutique, et un dispositif utilisés pour ce faire
CN105919955A (zh) * 2016-06-13 2016-09-07 佛山市腾瑞医药科技有限公司 一种鲁索利替尼制剂及其应用
HRP20240974T1 (hr) 2016-07-27 2024-10-25 Acceleron Pharma Inc. Pripravci za uporabu u liječenju mijelofibroze
WO2019140953A1 (fr) 2018-01-16 2019-07-25 深圳市塔吉瑞生物医药有限公司 Composé de diphénylaminopyrimidine inhibant l'activité kinase
EP3856189A4 (fr) * 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Procédés de traitement de troubles myéloprolifératifs
EP3856169A4 (fr) * 2018-09-25 2022-06-29 Impact Biomedicines, Inc. Procédés de traitement de troubles myéloprolifératifs
FR3092581A1 (fr) * 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2
KR20210145735A (ko) * 2019-02-12 2021-12-02 임팩트 바이오메디신스, 인코포레이티드 Jak2 저해제의 결정질 형태
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
US11306062B2 (en) 2019-10-29 2022-04-19 Johnson Matthey Public Limited Forms of fedratinib dihydrochloride
PL4076404T3 (pl) * 2019-12-20 2024-02-19 Intervet International B.V. Kompozycja farmaceutyczna pirazolu
WO2021207051A1 (fr) * 2020-04-06 2021-10-14 Bristol-Myers Squibb Company Méthodes de traitement de troubles respiratoires aigus
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
MX2023006939A (es) 2020-12-16 2023-08-08 Impact Biomedicines Inc Dosificacion de fedratinib.
MX2023009858A (es) 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
US20240358722A1 (en) 2021-09-14 2024-10-31 Impact Biomedicines, Inc. Methods of administering fedratinib

Family Cites Families (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003199A (en) 1930-05-31 1935-05-28 Johnson Frank James Automatic coal stoker
US2003149A (en) 1931-05-22 1935-05-28 Autographic Register Co Manifolding
US2003065A (en) 1931-06-20 1935-05-28 John R Ditmars Composition for coating sheets, fibrous stocks, and the like
US2004102A (en) 1932-02-24 1935-06-11 Daniel A Dickey Hollow steel propeller construction
US2004138A (en) 1932-11-30 1935-06-11 Byers A M Co Method of making wrought iron pipe
US2002165A (en) 1933-07-08 1935-05-21 Charles A Winslow Air cleaner
US2003187A (en) 1933-10-02 1935-05-28 Frederick H Shaw Automobile radio device
US2003166A (en) 1933-10-26 1935-05-28 Zancan Ottavio Front drive for motor cars
US2001051A (en) 1933-12-01 1935-05-14 Angelina Mariani Tamperproof meter box with cutout control and fuse drawer for electric meters
US2004092A (en) 1933-12-15 1935-06-11 John L Chaney Device for indicating the temperature of liquids
US2003060A (en) 1934-04-02 1935-05-28 Ernest L Heckert Thermostatic controlling device
US2667486A (en) 1951-05-24 1954-01-26 Research Corp 2,4-diamino pteridine and derivatives
IL44058A (en) 1973-02-02 1978-10-31 Ciba Geigy Ag 3amino-1,2,4-benzotriazine 1,4-di-noxide derivatives, their preparation and compositions for the control of microorganisms containing them
AU535258B2 (en) 1979-08-31 1984-03-08 Ici Australia Limited Benzotriazines
DE3205638A1 (de) 1982-02-17 1983-08-25 Hoechst Ag, 6230 Frankfurt Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US4490289A (en) 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US5616584A (en) 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
JP2598100B2 (ja) 1988-08-31 1997-04-09 キヤノン株式会社 電子写真感光体
US5214059A (en) 1989-07-03 1993-05-25 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5665543A (en) 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
US5041430A (en) 1989-09-18 1991-08-20 Du Pont Mereck Pharmaceutical Company Oral anticoagulant/platelet inhibitor low dose formulation
JPH03127790A (ja) 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
GB9003553D0 (en) 1990-02-16 1990-04-11 Ici Plc Herbicidal compositions
JP2839106B2 (ja) 1990-02-19 1998-12-16 キヤノン株式会社 電子写真感光体
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
IE74711B1 (en) 1990-07-27 1997-07-30 Ici Plc Fungicides
GB9016800D0 (en) 1990-07-31 1990-09-12 Shell Int Research Tetrahydropyrimidine derivatives
DE4025891A1 (de) 1990-08-16 1992-02-20 Bayer Ag Pyrimidyl-substituierte acrylsaeureester
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
HUT63941A (en) 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
US5438130A (en) 1993-01-15 1995-08-01 Cambridge Neuroscience, Inc. Fucosylated guanosine disulfates as excitatory amino acid antagonists
JPH0741461A (ja) 1993-05-27 1995-02-10 Eisai Co Ltd スルホン酸エステル誘導体
JPH0782183A (ja) 1993-09-09 1995-03-28 Canon Inc 液晶中間体化合物、液晶性化合物、高分子液晶化合物、高分子液晶共重合体化合物、それらの組成物、液晶素子および記録装置
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5530000A (en) 1993-12-22 1996-06-25 Ortho Pharmaceutical Corporation Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
CA2230894A1 (fr) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2241724A1 (fr) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Antagonistes du recepteur de vitronectine
JPH09274290A (ja) 1996-02-07 1997-10-21 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料用の現像液および処理方法
DK0939632T3 (da) 1996-02-23 2006-01-30 Lilly Co Eli Non-peptidyl vasopressin V1a antagonister
DE59707681D1 (de) 1996-10-28 2002-08-14 Rolic Ag Zug Vernetzbare, photoaktive Silanderivate
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
JP3734903B2 (ja) 1996-11-21 2006-01-11 富士写真フイルム株式会社 現像処理方法
JPH10153838A (ja) 1996-11-22 1998-06-09 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JP3720931B2 (ja) 1996-11-26 2005-11-30 富士写真フイルム株式会社 ハロゲン化銀写真感光材料の処理方法
CN1240010A (zh) 1996-12-04 1999-12-29 金伯利-克拉克环球有限公司 湿强度纸的制备方法
US5935383A (en) 1996-12-04 1999-08-10 Kimberly-Clark Worldwide, Inc. Method for improved wet strength paper
JP2001506271A (ja) 1996-12-23 2001-05-15 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての酸素またはイオウを含む複素環式芳香族化合物
JPH10207019A (ja) 1997-01-22 1998-08-07 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
DE59807348D1 (de) 1997-02-05 2003-04-10 Rolic Ag Zug Photovernetzbare Silanderivate
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JPH10260512A (ja) 1997-03-19 1998-09-29 Fuji Photo Film Co Ltd ハロゲン化銀感光材料の処理方法
JPH10310583A (ja) 1997-05-09 1998-11-24 Mitsubishi Chem Corp ピリドンアゾ系化合物、感熱転写用色素およびそれを使用した感熱転写材料
US6070126A (en) 1997-06-13 2000-05-30 William J. Kokolus Immunobiologically-active linear peptides and method of identification
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
DE69839735D1 (de) 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
CA2314401A1 (fr) 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Heteroaromatiques contenant de l'azote, presentant des groupes p1 a substitution ortho, et utilises en tant qu'inhibiteurs du facteur xa
US6200977B1 (en) 1998-02-17 2001-03-13 Tularik Inc. Pyrimidine derivatives
DE69943247D1 (de) 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EE04850B1 (et) 1998-03-27 2007-06-15 Janssen Pharmaceutica N.V. Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutamiseks HIV nakku
US6685938B1 (en) 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
DE19830181C1 (de) 1998-07-06 1999-09-30 Inter Control Koehler Hermann Mehrpolige elektrische Steckverbindung
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
ES2457396T3 (es) 1998-09-29 2014-04-25 Wyeth Holdings Llc 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas
ES2211175T3 (es) 1998-09-29 2004-07-01 Wyeth Holdings Corporation Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
EP1140862A4 (fr) 1998-12-23 2004-07-28 Bristol Myers Squibb Pharma Co INHIBITEURS DE LA THROMBINE OU DU FACTEUR Xa
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AU2871900A (en) 1999-02-04 2000-08-25 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
IL145870A0 (en) 1999-04-21 2002-07-25 American Cyanamid Co Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases
AU5020400A (en) 1999-05-20 2000-12-12 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
US6710221B1 (en) 1999-06-15 2004-03-23 Kimberly-Clark Worldwide, Inc. Absorbent articles incorporating color change graphics
BR0012046A (pt) 1999-07-01 2002-05-14 Ajinomoto Kk Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
WO2001007027A2 (fr) 1999-07-22 2001-02-01 Vertex Pharmaceuticals Incorporated Inhibiteurs d'helicase virale
HUP0203575A3 (en) 1999-07-23 2003-11-28 Shionogi & Co Pharmaceutical compositions containing th2 differentiation inhibitors and their use
AU6016000A (en) 1999-07-23 2001-02-13 Shionogi & Co., Ltd. Tricyclic compounds and drug compositions containing the same
MXPA02001448A (es) 1999-08-12 2002-07-02 American Cyanamid Co Farmacos antiinflamatorios no esteroides e inhibidores de cinasa del receptor del factor de crecimiento epidermico que contiene composicion para el tratamiento o la inhibicion de polipos colonicos y cancer colorrectal.
US6093838A (en) 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6127382A (en) 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
AU7683500A (en) 1999-10-12 2001-04-23 Takeda Chemical Industries Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
WO2001032628A1 (fr) 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Composes cyano utiles en tant qu"inhibiteurs du facteur xa
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
ES2281372T3 (es) 1999-12-29 2007-10-01 Wyeth Inhibidores de proteina-quinasa triciclicos.
US6153752A (en) 2000-01-28 2000-11-28 Creanova, Inc. Process for preparing heterocycles
AU2001228638A1 (en) 2000-01-28 2001-08-07 Astrazeneca Ab Chemical compounds
US20020165244A1 (en) 2000-01-31 2002-11-07 Yuhong Zhou Mucin synthesis inhibitors
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
MXPA02008023A (es) 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
WO2001062233A2 (fr) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Modulateurs de recepteurs de l'adenosine
US7105550B2 (en) 2000-03-01 2006-09-12 Christopher Love 2,4-disubstituted thiazolyl derivatives
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2001245401A1 (en) 2000-03-01 2001-09-12 Sumitomo Pharmaceuticals Company, Limited Hydrazones and analogs as cholesterol lowering agents
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP2001247411A (ja) 2000-03-09 2001-09-11 Tomono Agrica Co Ltd 有害生物防除剤
EP1263503B1 (fr) 2000-03-13 2005-11-02 Wyeth Holdings Corporation Ulisation de cyanoquinolines pour traiter ou empecher des polypes du colon
US6613917B1 (en) 2000-03-23 2003-09-02 Allergan, Inc. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
AR028261A1 (es) 2000-03-28 2003-04-30 Wyeth Corp Inhibidores triciclicos de la proteina quinasa
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
JP3831253B2 (ja) 2000-04-04 2006-10-11 塩野義製薬株式会社 高脂溶性化合物を含有する油性組成物
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
DE10024622A1 (de) 2000-05-18 2001-11-22 Piesteritz Stickstoff N-(2-Pyrimidinyl)(thio)phosphorsäuretriamide, Verfahren zu ihrer Herstellung und deren Verwendung als Mittel zur Regulierung bzw. Hemmung der enzymatischen Harnstoff-Hydrolyse
DE60114518T2 (de) 2000-07-06 2006-08-10 Fuji Photo Film Co. Ltd., Minamiashigara Flüssigkristallzusammensetzung, die Flüssigkristallmoleküle und Ausrichtungsmittel enthält
JP5000068B2 (ja) 2000-08-11 2012-08-15 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有用な複素環化合物
CA2422367C (fr) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Composes de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase
CA2425259A1 (fr) 2000-10-11 2002-04-18 Tularik, Inc. Modulation de fonction de ccr4
EP1337524A1 (fr) 2000-11-02 2003-08-27 AstraZeneca AB Quinolines substituees comme agents antitumoraux
EP1337513A1 (fr) 2000-11-02 2003-08-27 AstraZeneca AB Quinoleines 4 substitues en position 4 utilisees comme agents antitumoraux
CA2430037A1 (fr) 2000-11-20 2002-05-30 Michael S. South Aryl-et-heteroaryl-pyridines polycycliques substituees utiles dans l'inhibition selective de la cascade de la coagulation
US20070026433A1 (en) * 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
AU2002232919A1 (en) 2000-12-29 2002-07-16 Alteon, Inc. Method for treating fibrotic diseases or other indications
EP1353674A1 (fr) 2000-12-29 2003-10-22 Alteon, Inc. Methode de traitement du glaucome ivb
JP2002221770A (ja) 2001-01-24 2002-08-09 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
NZ527365A (en) 2001-02-23 2005-08-26 Merck & Co Inc N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
EP1370250A2 (fr) 2001-03-23 2003-12-17 Chugai Seiyaku Kabushiki Kaisha Ligands flt-1 et utilisations de ceux-ci dans le traitement des maladies reglable par l'angiogenesis
AU2002338642A1 (en) 2001-04-13 2002-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US20040157866A1 (en) 2001-04-30 2004-08-12 Hisashi Takasugi Amide compounds
US7271181B2 (en) 2001-05-11 2007-09-18 Vertex Pharmaceuticals Incorporated Inhibitors of p38
WO2002094766A1 (fr) 2001-05-18 2002-11-28 Nihon Nohyaku Co., Ltd. Derive de phtalamide, insecticide agricole et horticole et son utilisation
AU2002314252A1 (en) 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
ATE420077T1 (de) 2001-05-29 2009-01-15 Bayer Schering Pharma Ag Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
ES2445328T3 (es) 2001-05-30 2014-03-03 The Scripps Research Institute Sistema de suministro para ácidos nucleicos
CA2446756C (fr) 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Composes de thiazole inhibiteurs des proteines kinase
CA2452603A1 (fr) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines utilisees en tant qu'inhibiteurs des proteines kinases src et lck
US6861529B2 (en) 2001-07-06 2005-03-01 Pfizer Inc Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
DE10150614A1 (de) 2001-10-12 2003-04-30 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen
DE10150615A1 (de) 2001-10-12 2003-04-30 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte
DE10150610A1 (de) 2001-10-12 2003-04-30 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Amidbasen
WO2003032994A2 (fr) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
PL369259A1 (en) 2001-11-01 2005-04-18 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
MXPA04004177A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de amida como inhibidores de la glicogeno cintasa cinasa 3-beta.
BR0214485A (pt) 2001-11-27 2004-09-14 Wyeth Corp 3-cianoquinolinas como inibidores de egf-r e her2 quinases
AU2002344567A1 (en) 2001-11-28 2003-06-10 Daiso Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003206397B2 (en) 2002-01-04 2008-07-17 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
US20030166932A1 (en) 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN101050189A (zh) 2002-02-05 2007-10-10 惠氏公司 N－酰基－2－氨基－4－烷氧基－5－硝基苯甲酸类化合物的合成方法
WO2003066601A1 (fr) 2002-02-08 2003-08-14 Smithkline Beecham Corporation Composes de pyrimidine
US7338959B2 (en) 2002-03-01 2008-03-04 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (fr) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Derives de pyridinyl amino pyrimidine utilises dans le traitement des troubles de l'hyperproliferation
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004005418A2 (fr) 2002-07-02 2004-01-15 Kimberly-Clark Worldwide, Inc. Compositions adhesives elastomeres et stratifiees
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
US20050239852A1 (en) 2002-08-02 2005-10-27 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
DE10240261A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen
DE10240262A1 (de) 2002-08-31 2004-03-11 Clariant Gmbh Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen
CA2500727A1 (fr) 2002-10-03 2004-04-15 Targegen, Inc. Agents vasculo-statiques et procedes d'utilisation de ceux-ci
US20050282814A1 (en) 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
AU2003279795A1 (en) 2002-10-04 2004-05-04 Caritas St.Elisabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization
WO2004037176A2 (fr) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones et derives de celles-ci comme inhibiteurs du facteur xa
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
AU2003295396B2 (en) 2002-11-04 2009-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl-pyramidine derivatives as JAK inhibitors
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
AU2003280188A1 (en) 2002-12-06 2004-06-30 Warner-Lambert Company Llc Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
WO2004054186A1 (fr) 2002-12-12 2004-06-24 Fujitsu Limited Appareil de relais de donnees, dispositif de memoire associative et dispositif de memoire associative utilisant un procede de recherche d'information
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2507699A1 (fr) 2002-12-20 2004-07-15 Pharmacia Corporation Acides heteroarylalcanoiques en tant qu'antagonistes du recepteur d'integrine
JP2006514050A (ja) 2002-12-20 2006-04-27 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのβ−アミノ酸化合物のＲ異性体
AU2003294142A1 (en) 2002-12-24 2004-07-22 Astrazeneca Ab Therapeutic quinazoline derivatives
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
CN102151270A (zh) 2003-02-07 2011-08-17 詹森药业有限公司 预防hiv感染的嘧啶衍生物
AP2005003365A0 (en) 2003-02-07 2005-09-30 Janssen Pharmaceutica Nv Hiv inhibiting 1, 2, 4-triazines.
WO2004071426A2 (fr) 2003-02-11 2004-08-26 Kemia Inc. Composes destines au traitement d'une infection virale
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2559670A1 (fr) 2003-04-14 2004-10-28 Gabor Pragai Formulations ameliorees de maleate d'amlodipine
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004097504A1 (fr) 2003-04-24 2004-11-11 Ocular Sciences Inc. Lentilles de contact a base d'hydrogel, systemes d'emballage et procedes de production associes
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
SG145749A1 (en) 2003-08-15 2008-09-29 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
BRPI0414544A (pt) 2003-09-18 2006-11-07 Novartis Ag 2,4-di-(fenilamino) pirimidinas úteis no tratamento de transtornos proliferativos
CA2567574C (fr) 2004-04-08 2013-01-08 Targegen, Inc. Inhibiteurs benzotriazine de kinases
RU2468021C2 (ru) 2004-08-25 2012-11-27 Таргеджен, Инк. Гетероциклические соединения и их применение
US7210697B2 (en) 2004-12-16 2007-05-01 Tricam International, Inc. Convertible handle
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
KR20070113288A (ko) 2005-03-16 2007-11-28 탈자진 인코포레이티드 피리미딘 화합물 및 사용 방법
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Traitement anticancereux
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
AU2006254825A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
WO2006137658A1 (fr) 2005-06-20 2006-12-28 Dongbu Hitek Co., Ltd. Nouveaux derives thiazole 1,3 substitues ou sels pharmaceutiquement acceptables de ces derniers presentant une activite d'inhibition de l'immunosuppression ou de l'inflammation, composes intermediaires ou sels pharmaceutiquement acceptables de ces derniers, procede de preparation de ces derniers et compositions pharmaceutiq
JP2009500317A (ja) 2005-06-29 2009-01-08 パナセア バイオテック リミテッド 放出特性改良医薬組成物およびその製造方法
WO2007008541A2 (fr) 2005-07-08 2007-01-18 Kalypsys, Inc. Modificateurs d'absorption de cholesterol cellulaire
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP2270014A1 (fr) 2005-09-22 2011-01-05 Incyte Corporation Inhibiteurs de l'azépine de janus kinases
US20070072682A1 (en) 2005-09-29 2007-03-29 Crawford James T Iii Head to head electronic poker game assembly and method of operation
UA109412C2 (uk) * 2005-11-01 2015-08-25 5-метил-n2-[4-(4-метилпіперазин-1-іл)феніл]-піримідин-2,4-діамін та його застосування в способі одержання сполуки
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
AU2006309013B2 (en) 2005-11-01 2012-06-28 Impact Biomedicines, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20070161645A1 (en) 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
CA2628474A1 (fr) 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Modulateurs de kinase de type pyrimidinylthiophene
WO2007069274A2 (fr) 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Composition pharmaceutique
PH12012501003B1 (en) 2005-11-16 2018-04-06 Cti Biopharma Corp Oxygen linked pyrimidine derivatives
HUE025173T2 (hu) 2005-12-13 2016-01-28 Incyte Corp Heteroaril-szubsztituált pirrollo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
US8440663B2 (en) * 2006-01-30 2013-05-14 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
JP5844028B2 (ja) * 2006-04-04 2016-01-13 ケージー アクキュイシチオン エルエルシー 抗血小板薬及び酸阻害薬を含む経口剤形
US7691858B2 (en) 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
EP2037918A2 (fr) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Formules pharmaceutiques de pimavansérine
WO2008008234A1 (fr) 2006-07-07 2008-01-17 Targegen, Inc. Inhibiteurs de type 2-amino-5-substituant-pyrimidines
MX2009000769A (es) 2006-07-21 2009-01-28 Novartis Ag Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US20110243853A1 (en) * 2006-10-25 2011-10-06 Jamieson Catriona Helen M Models of erythropoiesis
EP3070090B1 (fr) 2007-06-13 2018-12-12 Incyte Holdings Corporation Utilisation des sels de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile
DE102007034947B4 (de) * 2007-07-26 2009-06-18 Siemens Ag Vorrichtung zum Entladen eines Stapels von auf ihren Schmalseiten stehenden flachen Gegenständen
JP2010536371A (ja) * 2007-08-21 2010-12-02 ノダリティ，インコーポレイテッド 診断方法、予後および治療方法
WO2009046416A1 (fr) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines en tant qu'inhibiteurs de kinases jak
US20100310563A1 (en) * 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
US20100016218A1 (en) * 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
JP2011530517A (ja) 2008-08-05 2011-12-22 ターゲジェン インコーポレーティッド サラセミアを処置する方法
PT2376500E (pt) 2008-12-11 2015-06-02 Cti Biopharma Corp Sal maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa- 5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
PL2229938T3 (pl) 2009-03-13 2012-09-28 Sanovel Ilac Sanayi Ve Ticaret As Kompozycje ezetymibu
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
WO2011012687A2 (fr) 2009-07-31 2011-02-03 Basf Se Composés phosphine-borane contenant des groupes imidazole et procédé de production de composés phosphorés contenant des groupes imidazole
EP2470534A4 (fr) 2009-08-24 2013-02-27 Merck Sharp & Dohme L'inhibition de jak bloque les toxicités associées à l'arn d'interférence
CA2816957A1 (fr) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procedes de traitement de la myelofibrose
WO2013013195A1 (fr) 2011-07-21 2013-01-24 Sanofi Compositions et méthodes de traitement de la maladie de vasquez et de la thrombocythémie essentielle
WO2013059548A1 (fr) 2011-10-19 2013-04-25 Sanofi Compositions et méthodes de traitement du cancer à l'aide d'un inhibiteur de jak2

Also Published As

Publication number Publication date
MY161164A (en) 2017-04-14
US20130252988A1 (en) 2013-09-26
UA114076C2 (xx) 2017-04-25
US20130243853A1 (en) 2013-09-19
WO2012061833A1 (fr) 2012-05-10
SI2635282T1 (sl) 2023-01-31
ECSP13012658A (es) 2013-08-30
TWI531389B (zh) 2016-05-01
HUE060254T2 (hu) 2023-02-28
CA2816957A1 (fr) 2012-05-10
KR20180122029A (ko) 2018-11-09
CA2816710A1 (fr) 2012-05-10
CL2013001252A1 (es) 2014-03-28
MX2013005020A (es) 2013-07-29
DOP2013000097A (es) 2013-11-30
CN103282036A (zh) 2013-09-04
RU2013126121A (ru) 2015-01-27
KR101940979B1 (ko) 2019-01-23
WO2012060847A1 (fr) 2012-05-10
HRP20221269T1 (hr) 2022-12-23
PE20140389A1 (es) 2014-03-26
BR112013011184A2 (pt) 2018-01-30
KR102131241B1 (ko) 2020-07-07
KR20130137647A (ko) 2013-12-17
CN108125923A (zh) 2018-06-08
TW201306882A (zh) 2013-02-16
EP2635282A4 (fr) 2014-04-30
CN103282036B (zh) 2018-01-26
US20210244735A1 (en) 2021-08-12
PT2635282T (pt) 2023-01-05
RS63996B1 (sr) 2023-03-31
CO6801724A2 (es) 2013-11-29
US10391094B2 (en) 2019-08-27
LT2635282T (lt) 2022-12-12
AU2011323108B2 (en) 2015-12-17
MX360246B (es) 2018-10-26
SMT202200453T1 (it) 2023-01-13
EP4159216A1 (fr) 2023-04-05
JP2013541595A (ja) 2013-11-14
ES2930650T3 (es) 2022-12-20
KR20240029118A (ko) 2024-03-05
DK2635282T3 (da) 2022-10-17
NI201300038A (es) 2013-09-09
KR20200083676A (ko) 2020-07-08
PL2635282T3 (pl) 2023-02-06
EP2635282A1 (fr) 2013-09-11
RU2616262C2 (ru) 2017-04-13
MX381913B (es) 2025-03-13
SG190134A1 (en) 2013-06-28
AU2011323108A1 (en) 2013-05-09
AU2010363329A1 (en) 2013-05-09
US20240293406A1 (en) 2024-09-05
IL226101A0 (en) 2013-06-27
IL226101A (en) 2017-12-31
EP2635282B1 (fr) 2022-09-28
NZ611363A (en) 2015-09-25
US20190381041A1 (en) 2019-12-19
ZA201303423B (en) 2015-06-24
PH12013500924A1 (en) 2013-07-08
JP6133211B2 (ja) 2017-05-24

Similar Documents

Publication Publication Date Title
MA34723B1 (fr) Compositions et méthodes de traitement de la myélofibrose
MX2009007661A (es) Inhibidores de mek.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA202092581A1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
EA200700225A1 (ru) Аналоги тетрапептида
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
DE602004013563D1 (de) Rantagonisten
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA201790267A1 (ru) Новые модуляторы киназ
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
EP2134346A4 (fr) Inhibiteurs de janus kinases et/ou protéine kinase-1 dépendant de la 3-phosphoinositide